Colon-targeted dexamethasone microcrystals with pH-sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease.
Carbohydr Polym
; 198: 434-442, 2018 Oct 15.
Article
em En
| MEDLINE
| ID: mdl-30093020
ABSTRACT
Oral colon-targeted drug delivery has gained popularity as an effective strategy for treatment of inflammatory bowel disease (IBD). In this study, we prepared colon-targeted dexamethasone microcrystals (DXMCs) coated with multilayers of chitosan oligosaccharide (CH), alginate (AG), and finally Eudragit S 100 (ES) (ES1AG4CH5-DXMCs) using a layer-by-layer (LBL) coating technique. Particle size, surface charge, in vitro drug release, and in vivo anti-inflammatory activity of ES1AG4CH5-DXMCs were evaluated. ES1AG4CH5-DXMCs had an average particle size of 2.34⯱â¯0.19⯵m and a negative surface charge of - 48⯱â¯9â¯mV. ES1AG4CH5-DXMCs demonstrated pH-dependent dexamethasone release, avoiding initial burst drug release in acidic pH conditions of the stomach and small intestine, and providing subsequent sustained drug release in the colonic pH. Importantly, ES1AG4CH5-DXMCs exhibited a significant therapeutic activity in a mouse model of colitis compared to other DXMCs. Overall, the LBL-coated DXMCs presented here could be a promising colon-targeted therapy for IBD.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ácidos Polimetacrílicos
/
Dexametasona
/
Sistemas de Liberação de Medicamentos
/
Colite
/
Quitosana
/
Alginatos
/
Anti-Inflamatórios
Tipo de estudo:
Diagnostic_studies
Limite:
Animals
Idioma:
En
Revista:
Carbohydr Polym
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Coréia do Sul